Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.8.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Operating expenses        
Research and development $ 88,550 $ 80,525 $ 241,302 $ 675,840
General and administrative 673,080 775,623 2,631,408 2,882,682
Total operating expenses 761,630 856,148 2,872,710 3,558,522
Operating loss (761,630) (856,148) (2,872,710) (3,558,522)
Other expense (income)        
Change in fair value of warrant liability (281,497) 27,665 (320,495) (1,584,969)
Change in fair value of conversion rights of Series B preferred stock 0 61,058 (88,532) 82,872
Net Loss before income taxes (480,133) (944,871) (2,463,683) (2,056,425)
Provision for income taxes   400 2,431 1,200
Net loss (480,133) (945,271) (2,466,114) (2,057,625)
Less: Preferred deemed dividend     711,000  
Net loss applicable to common shareholders $ (480,133) $ (945,271) $ (3,177,114) $ (2,057,625)
Basic earnings per common share (in dollars per share) $ (0.02) $ (0.05) $ (0.12) $ (0.10)
Diluted earnings per common share (in dollars per share) $ (0.02) $ (0.05) $ (0.12) $ (0.10)
Weighted average shares of common stock outstanding        
Basic (in shares) 30,191,744 19,913,163 27,068,308 19,910,426
Diluted (in shares) 30,191,744 19,913,163 27,068,308 19,910,426